Maharashtra, India

Ajit Borhade

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Piramal Life Sciences Limited. Active years: 2011.


% Patents Active = 100.0



Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ajit Borhade: Innovator in Enantioselective Synthesis

Introduction

Ajit Borhade is a notable inventor based in Maharashtra, India. He has made significant contributions to the field of chemistry, particularly in the synthesis of complex organic compounds. His work focuses on developing innovative methods that can have a profound impact on medical treatments.

Latest Patents

Ajit Borhade holds a patent for the "Enantioselective synthesis of pyrrolidines substituted with flavones, and intermediates thereof." This invention relates to the enantioselective synthesis of the (+)-trans enantiomer of pyrrolidines, which are inhibitors of cyclin-dependent kinases. These compounds can be utilized in the treatment of proliferative disorders such as cancer, showcasing the potential of his research in addressing critical health issues. He has 1 patent to his name.

Career Highlights

Ajit Borhade is currently associated with Piramal Life Sciences Limited, where he continues to advance his research and development efforts. His work at this esteemed organization allows him to collaborate with other talented professionals in the field.

Collaborations

Some of his notable coworkers include Meenakshi Sivakumar and Manoj Shukla. Their collective expertise contributes to the innovative environment at Piramal Life Sciences Limited.

Conclusion

Ajit Borhade's contributions to enantioselective synthesis highlight his role as a key innovator in the field of chemistry. His work not only advances scientific knowledge but also holds promise for future medical applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…